Stoke Therapeutics (STOK) Stock Price, News & Analysis

Company Overview

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

Key Stats

• Today's Range: $9.34 to $9.83
• 50-Day Range: $5.90 to $10.05
• 52-Week Range: $5.35 to $17.58
• Volume: 453,308 shs
• Average Volume: 709,422 shs
• Market Capitalization: $531.23 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $23.20
• Consensus Rating: Buy

Stoke Therapeutics Stock Analysis - MarketRank™

Stoke Therapeutics scored higher than 80% of companies evaluated by MarketBeat, and ranked 200th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Stoke Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.29, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Stoke Therapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Stoke Therapeutics are expected to decrease in the coming year, from ($2.01) to ($2.27) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Stoke Therapeutics is -4.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Stoke Therapeutics is -4.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Stoke Therapeutics has a P/B Ratio of 2.73. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

24.84% of the float of Stoke Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Stoke Therapeutics has a short interest ratio ("days to cover") of 14.1, which indicates bearish sentiment.

Change versus previous month

Short interest in Stoke Therapeutics has recently decreased by 9.11%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Stoke Therapeutics does not currently pay a dividend.

Dividend Growth

Stoke Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.8 / 5
• Environmental Score: -0.59

Percentage of Shares Shorted

24.84% of the float of Stoke Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Stoke Therapeutics has a short interest ratio ("days to cover") of 14.1, which indicates bearish sentiment.

Change versus previous month

Short interest in Stoke Therapeutics has recently decreased by 9.11%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 1.16

News Sentiment

Stoke Therapeutics has a news sentiment score of 1.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Stoke Therapeutics this week, compared to 5 articles on an average week.

MarketBeat Follows

8 people have added Stoke Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 700% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Stoke Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $143,332.00 in company stock.

Percentage Held by Insiders

11.30% of the stock of Stoke Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

STOK Stock Analysis - Frequently Asked Questions

How have STOK shares performed this year?

Stoke Therapeutics' stock was trading at $11.03 on January 1st, 2025. Since then, STOK stock has decreased by 11.8% and is now trading at $9.73.
View the best growth stocks for 2025 here.

How were Stoke Therapeutics' earnings last quarter?

Stoke Therapeutics, Inc. (NASDAQ:STOK) announced its quarterly earnings data on Monday, March, 24th. The company reported ($0.18) EPS for the quarter, beating analysts' consensus estimates of ($0.56) by $0.38. The company had revenue of $22.61 million for the quarter, compared to analysts' expectations of $4.20 million. Stoke Therapeutics had a negative net margin of 629.90% and a negative trailing twelve-month return on equity of 54.45%.

When did Stoke Therapeutics IPO?

Stoke Therapeutics (STOK) raised $100 million in an initial public offering on Wednesday, June 19th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and Credit Suisse served as the underwriters for the IPO and Canaccord Genuity was co-manager.

Who are Stoke Therapeutics' major shareholders?

Stoke Therapeutics' top institutional investors include Redmile Group LLC (8.22%), Vanguard Group Inc. (5.10%), Siren L.L.C. (4.12%) and Siren L.L.C. (4.12%). Insiders that own company stock include Skorpios Trust, Barry Ticho, Jonathan Allan and Stephen J Tulipano.
View institutional ownership trends.

How do I buy shares of Stoke Therapeutics?

Shares of STOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Stoke Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Stoke Therapeutics investors own include Enovix (ENVX), Rambus (RMBS), COMPASS Pathways (CMPS), Globant (GLOB), Ginkgo Bioworks (DNA), Toast (TOST) and Saia (SAIA).

Company Calendar

• Last Earnings: 3/24/2025
• Today: 5/29/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:STOK
• CIK: 1623526
• Web: www.stoketherapeutics.com
• Phone: (781) 430-8200
• Fax: N/A
• Employees: 100
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $23.20
• High Stock Price Target: $35.00
• Low Stock Price Target: $17.00
• Potential Upside/Downside: +138.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.29
• Research Coverage: 7 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $0.79
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$104.70 million
• Net Margins: -629.90%
• Pretax Margin: -629.90%
• Return on Equity: -54.45%
• Return on Assets: -40.77%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.09
• Quick Ratio: 5.09

Sales & Book Value

• Annual Sales: $190.91 million
• Price / Sales: 2.78
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.57 per share
• Price / Book: 2.73

Miscellaneous

• Outstanding Shares: 54,597,000
• Free Float: 46,982,000
• Market Cap: $531.23 million
• Optionable: Optionable
• Beta: 1.20